SCHEMBL3065262

SCHEMBL3065262

c1ccc(C(c2ccncc2)c2cnc[nH]2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.59
SLC6A4 P31645 3/20 0.59
SLC6A3 Q01959 3/20 0.59
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.46
HRH3 Q9Y5N1 5/20 0.45
HRH4 Q9H3N8 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
HRH1 P35367 1/20 0.45
CFTR P13569 1/20 0.44
GOPC Q9HD26 1/20 0.44
CPA1 P15085 1/20 0.43
CYP19A1 P11511 2/20 0.42
ADRA2A P08913 3/20 0.42
ADRA2B P18089 3/20 0.42
ADRA2C P18825 3/20 0.42
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3070057 0.86 SLC6A2 (0.65) SLC6A2SLC6A4SLC6A3KMT2AATM
SCHEMBL3073542 0.83 CYP19A1 (0.49) SLC6A2SLC6A4SLC6A3HRH3HRH4
SCHEMBL3066082 0.81 SLC6A2 (0.62) SLC6A2SLC6A4SLC6A3KMT2AHRH3
SCHEMBL3074087 0.81 ADRA2A (0.52) SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2
SCHEMBL3055369 0.81 CYP19A1 (0.44) SLC6A2SLC6A4SLC6A3HRH3HRH4
SCHEMBL27911641 0.80 HRH3 (0.40) SLC6A2SLC6A4SLC6A3HRH3HRH4
SCHEMBL1639415 0.79 CYP19A1 (0.55) CYP19A1ADRA2AADRA2BADRA2CADRA1D
SCHEMBL1638361 0.77 ADRA2A (0.55) SLC6A2CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL1482044 0.77 SLC6A2 (0.62) SLC6A2SLC6A4SLC6A3HRH3HRH4
SCHEMBL10000118 0.77 ADRA2A (0.53) SLC6A2SLC6A4SLC6A3CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101743240-B ((phenyl) imidazolyl) methyl heteroaryl compounds ALLERGAN INC 2013-07-17 CN disclosed
EP-2155715-B1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS ALLERGAN INC (US) 2013-03-13 EP disclosed
US-20100273814-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS SINHA SANTOSH C 2010-10-28 US disclosed
CN-101743240-A ((phenyl) imidazolyl) methyl heteroaryl compounds ALLERGAN INC 2010-06-16 CN disclosed
EP-2155715-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS ALLERGAN, INC. (US) 2010-02-24 EP disclosed
WO-2008141312-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS ALLERGAN, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273814-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS CYP11B2, TPMT, COXFA4L2 SLC6A2 2046/4885SLC6A4 1930/4885SLC6A3 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.